⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S15 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Rohit Thummalapalli Biagio Ricciuti Chaitanya Bandlamudi Daniel M. Muldoon Hira Rizvi Arielle Elkrief Jia Luo Joao V. Alessi Federica Pecci Giuseppe Lamberti Alessandro Di Federico Lingzhi Hong Jianjun Zhang John V. Heymach Don L. Gibbons Andrew J. Plodkowski Vignesh Ravichandran Mark T.A. Donoghue Chad Vanderbilt Marc Ladanyi Charles M. Rudin Mark G. Kris Gregory J. Riely Jamie E. Chaft Matthew D. Hellmann Natalie I. Vokes Mark M. Awad Adam J. Schoenfeld

View at Publisher

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Fraction of subclonal non-synonymous mutations among patients with long-term response (LTR), short-term response (STR), and progressive disease (PD).

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Thummalapalli et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db643587522717 https://doi.org/10.1158/1078-0432.27033046

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S15 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
2Supplementary Figure S1 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
3Supplementary Figure S1 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
4Supplementary Figure S10 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
5Supplementary Figure S10 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024

Supplementary Figure S12 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
Supplementary Figure S12 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024
Supplementary Figure S11 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer2024